{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:38:19Z","timestamp":1790854699104,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Mukh-Mantri Punjab Hepatitis C Relief Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jhep.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T19:45:36Z","timestamp":1563392736000},"page":"1076-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting"],"prefix":"10.1016","volume":"71","author":[{"given":"Radha K.","family":"Dhiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahaj","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Satsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.07.006_b0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jceh.2016.09.005","article-title":"Tackling the hepatitis C disease burden in Punjab, India","volume":"6","author":"Dhiman","year":"2016","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200461","article-title":"The burden of hepatitis C virus infection in Punjab, India: a population-based serosurvey","volume":"13","author":"Sood","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.07.006_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2019.07.006_b0020","first-page":"104","article-title":"Consensus statement of HCV task force of the Indian national association for study of the liver (INASL). Part I: status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176503","article-title":"Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India","volume":"12","author":"Aggarwal","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.07.006_b0030","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis c direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin Infectious Dis"},{"key":"10.1016\/j.jhep.2019.07.006_b0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jceh.2017.08.003","article-title":"Chronic hepatitis C: do generics work as well as branded drugs?","volume":"7","author":"Premkumar","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0040","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection Updated version, April 2016 available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/111747\/1\/9789241548755_eng.pdf?ua=1&ua=1 [accessed 20th July 2018]."},{"key":"10.1016\/j.jhep.2019.07.006_b0045","unstructured":"Standard Operating Procedures Vol 1. MMPHCRF. Downloaded from http:\/\/pbhealth.gov.in\/SOPs%20for%20MMPHCRF.pdf."},{"key":"10.1016\/j.jhep.2019.07.006_b0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jceh.2014.06.011","article-title":"Future of therapy for hepatitis C in India: a matter of accessibility and affordability?","volume":"4","author":"Dhiman","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0055","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of hepatitis C treatment by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.07.006_b0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MPG.0000000000002139","article-title":"Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health perspective","volume":"68","author":"Dhiman","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2019.07.006_b0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2055-6640(20)30691-9","article-title":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C","volume":"2","author":"Hill","year":"2016","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jhep.2019.07.006_b0070","unstructured":"Gilead: access partnerships [website]. http:\/\/www.gilead.com\/responsibility\/developing-world-access\/access%20partnerships [accessed 20th July 2018], 78."},{"key":"10.1016\/j.jhep.2019.07.006_b0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jhep.2018.02.037","article-title":"Real-world data on antiviral treatments for hepatitis C virus infections: can we define intention to treat or per protocol analyses?","volume":"69","author":"Ojha","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0080","unstructured":"ICH E3. Available from: ICH E3. Available from: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E3\/E3_Q_As_Step4.pdf. [Last accessed on 25th May 2019]."},{"key":"10.1016\/j.jhep.2019.07.006_b0085","unstructured":"WHO. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries PICO 4 Care (Fibrosis) \u2013 Decision Making Table. Available from https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/133823\/WHO_HIV_2014.37_eng.pdf;jsessionid=228B04F4F414A896B7606607704B39A7?sequence=1. [Last accessed 21st April 2019]."},{"key":"10.1016\/j.jhep.2019.07.006_b0090","unstructured":"WHO global health sector strategy on viral hepatitis Geneva: World Health Organization; 2016 (http:\/\/ apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1, 20 July 2016)."},{"key":"10.1016\/j.jhep.2019.07.006_b0095","unstructured":"Global report on access to hepatitis C treatment. Focus on overcoming barriers. Available from http:\/\/apps.who.int\/iris\/bitstream\/10665\/260445\/1\/WHO-CDS-HIV-18.4-eng.pdf?ua=1. [Accessed 21st July 2018]."},{"key":"10.1016\/j.jhep.2019.07.006_b0100","unstructured":"World Health Organization news event. Available from https:\/\/www.who.int\/hepatitis\/news-events\/hepatitis-testing-treatment-increase\/en\/."},{"key":"10.1016\/j.jhep.2019.07.006_b0105","first-page":"33A","article-title":"Educate, test and treat model towards elimination of hepatitis C in Egypt: Implementation in 63 villages","volume":"68","author":"Shiha","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.07.006_b0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/apt.13923","article-title":"Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt","volume":"45","author":"Elsharkawy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.07.006_b0115","unstructured":"Launch of a nationwide hepatitis C elimination program \u2013 Georgia. Atlanta: Centers for Disease Control and Prevention; 2015. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6428a2.htm [accessed 12 July 2018]."},{"key":"10.1016\/j.jhep.2019.07.006_b0120","author":"Tsertsvadze","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0125","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2019.07.006_b0130","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.45788","article-title":"Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran","volume":"17","author":"Hajarizadeh","year":"2017","journal-title":"Hepat Mon"},{"issue":"8","key":"10.1016\/j.jhep.2019.07.006_b0135","doi-asserted-by":"crossref","first-page":"e0221769","DOI":"10.1371\/journal.pone.0221769","article-title":"Cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India","volume":"14","author":"Chugh","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.07.006_b0140","first-page":"1339","article-title":"Intention-to-treat principle","volume":"165","author":"Montori","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.jhep.2019.07.006_b0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.jhep.2019.07.006_b0150","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.325.7365.652","article-title":"Post-randomization exclusions: the intention to treat principle and excluding patients from analysis","volume":"325","author":"Fergusson","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2019.07.006_b0155","article-title":"Deviation from intention to treat analysis in randomized trials and treatment effect estimates: meta-epidemiological study","volume":"27","author":"Abraha","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2019.07.006_b0160","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/j.gastro.2017.10.016","article-title":"Cost-effectiveness of access expansion to treatment of hepatitis C virus infection through primary care providers","volume":"153","author":"Rattay","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.07.006_b0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/bmjinnov-2016-000141","article-title":"Telementoring with project ECHO: a pilot study in Europe","volume":"3","author":"N\u00ed Cheallaigh","year":"2017","journal-title":"BMJ Innov"},{"key":"10.1016\/j.jhep.2019.07.006_b0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4254\/wjh.v8.i11.509","article-title":"Extension for community health outcomes-hepatitis C: small steps carve big footprints in the allocation of scarce resources for hepatitis C virus treatment to remote developing areas","volume":"8","author":"Tahan","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2019.07.006_b0175","unstructured":"National Viral Hepatitis Control Program-Operational guidelines, 2018 by Ministry of Health and Family Welfare, Government of India. Available from https:\/\/www.nhp.gov.in\/national-viral-hepatitis-control-program-(nvhcp)_pg. [last accessed 21st April 2019]."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819304143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819304143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:36:26Z","timestamp":1759174586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819304143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0168827819304143"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.07.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}